Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Novel therapy in multiple myeloma.

Agustin Avilés1, Natividad Neri, M Jesús Nambo

  • 1Oncology Research Unit, Department of Hematology, Oncology Hospital, National Medical Center, IMSS, México, D.F. Mexico. agaviles@avantel.net

Investigational New Drugs
|September 1, 2005
PubMed
Summary

This study introduces a new, non-cytotoxic DAI regimen for older multiple myeloma patients, showing an 80% response rate and mild toxicity. The treatment demonstrated high event-free and overall survival, suggesting a promising therapeutic option.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A Phase 1 Study to Assess the Effect of Fruquintinib on the Pharmacokinetics of P-gp and BCRP Substrates in Healthy Subjects.

Clinical and translational science·2025
Same author

Evaluation of Potential Effects of CYP3A Inhibition and CYP3A Induction on the Pharmacokinetics of Fruquintinib in Healthy Subjects.

Clinical pharmacology in drug development·2025
Same author

Effects of Hepatic or Renal Impairment on Pharmacokinetics of Fruquintinib.

Journal of clinical pharmacology·2025
Same author

The Pulse of Primary Care.

Journal of general internal medicine·2025
Same author

Assessment of Food Effect and pH-Dependent Drug-Drug Interactions of Fruquintinib in Healthy Subjects.

Clinical and translational science·2025
Same author

Phase 1/1b open-label, dose-escalation study of fruquintinib in patients with advanced solid tumors in the United States.

Investigational new drugs·2023

Area of Science:

  • Hematology
  • Oncology
  • Clinical Therapeutics

Background:

  • Treatment for multiple myeloma in patients over 65 is challenging due to intensive chemotherapy toxicity.
  • Current therapeutic approaches for elderly multiple myeloma patients require safer, effective alternatives.

Purpose of the Study:

  • To evaluate the efficacy and safety of a novel non-cytotoxic regimen (DAI) for older patients with multiple myeloma.
  • To assess the overall response rate, event-free survival, and overall survival in this patient population.

Main Methods:

  • A Phase II study enrolled 41 elderly multiple myeloma patients.
  • Patients received a 6-cycle regimen of dexamethasone, all-trans retinoic acid, and interferon alfa (DAI), followed by thalidomide and dexamethasone maintenance.
  • Treatment outcomes were assessed based on response rates, progression-free survival, and toxicity.

Related Experiment Videos

Main Results:

  • An overall response rate of 80% was observed, with 43% achieving complete response.
  • At a median follow-up of 36 months, 3-year event-free survival was 100% and overall survival was 91%.
  • The DAI regimen exhibited mild toxicity, with all patients tolerating the planned doses.

Conclusions:

  • The novel non-cytotoxic DAI regimen is effective and well-tolerated in older patients with multiple myeloma.
  • This regimen offers a promising alternative to conventional chemotherapy, warranting further investigation in controlled trials.